Vanguard Group Inc Revance Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,625,091 shares of RVNC stock, worth $14.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,625,091

Previous 5,733,699 1.89%

Holding current value

$14.5 Million

Previous $14.7 Million 1.89%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	N/A	-108,608 Reduced 1.89%	5,625,091 $14.5 Million
Q3 2024 Nov 13, 2024	SELL	$2.57 - $2.57 $670,153 - $670,153	-260,760 Reduced 4.35%	5,733,699 $14.7 Million
Q2 2024 Aug 13, 2024	BUY	$2.34 - $4.73 $1.39 Million - $2.82 Million	596,053 Added 11.04%	5,994,459 $15.4 Million
Q1 2024 May 10, 2024	BUY	$4.65 - $9.31 $1.53 Million - $3.06 Million	328,781 Added 6.49%	5,398,406 $26.6 Million
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $1.62 Million - $3.12 Million	278,166 Added 5.81%	5,069,625 $44.6 Million
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $1.59 Million - $3.48 Million	138,683 Added 2.98%	4,791,459 $55 Million
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $1.31 Million - $1.99 Million	53,031 Added 1.15%	4,652,776 $118 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $1.9 Million - $3.65 Million	103,429 Added 2.3%	4,599,745 $148 Million
Q4 2022 Feb 10, 2023	BUY	$18.32 - $30.66 $3.36 Million - $5.62 Million	183,420 Added 4.25%	4,496,316 $83 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $8.74 Million - $17.4 Million	609,841 Added 16.47%	4,312,896 $116 Million
Q2 2022 Aug 12, 2022	BUY	$11.52 - $20.4 $665,210 - $1.18 Million	57,744 Added 1.58%	3,703,055 $51.2 Million
Q1 2022 May 13, 2022	BUY	$12.36 - $20.31 $531,653 - $873,614	43,014 Added 1.19%	3,645,311 $71.1 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $216,704 - $484,715	17,392 Added 0.49%	3,602,297 $58.8 Million
Q3 2021 Nov 12, 2021	SELL	$25.78 - $33.21 $717,792 - $924,666	-27,843 Reduced 0.77%	3,584,905 $99.9 Million
Q2 2021 Aug 13, 2021	BUY	$26.8 - $31.84 $96.8 Million - $115 Million	3,612,748 New	3,612,748 $107 Million

Others Institutions Holding RVNC

# of Institutions

208

Shares Held

80.9M

Call Options Held

2.26M

Put Options Held

5.48M

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Revance Therapeutics, Inc. Transaction History